×

Targovax reports immune response with reduced number of TG01 vaccinations

OSLO, Norway, April 14, 2016 (GLOBE NEWSWIRE) -- Targovax has conducted an interim DTH immunological response evaluation assessing early immune activation following administration of TG01 in combination with gemcitabine in the ongoing Phase I/II trial. The results show that the modified and reduced vaccination schedule generated similar 8-week immune responses in patients with pancreatic cancer, as seen in the initial cohort.

In March 2015, Targovax announced the immune results from the initial part of the trial. 18 out of 19 patients were eligible for immune response assessment and 15 patients had established a detectable immune response. Targovax now announces, in a second part of the trial, where the overall number of vaccinations have been reduced, that 4 of the first recruited 5 patients (of a total of up to 13 patients) showed an 8-week immune response.

The trial is an open label, phase I/II trial of TG01/GM-CSF in combination with gemcitabine as adjuvant therapy for treating patients with resected adenocarcinoma of the pancreas.

"It is encouraging to see that these interim DTH data from the cohort which received a reduced number of TG01 vaccinations show a similar level of 8-week immune activation as we saw in the earlier cohort which had received a higher number of TG01 vaccinations. We look forward to subsequent immune activation data for the remaining patients in this modified cohort and survival data which is expected during 2017 and 2018", says Gunnar Gårdemyr, CEO of Targovax.

About Targovax: "Arming the patient's immune system to fight cancer"

Targovax is a clinical stage immuno-oncology company developing targeted immunotherapy treatments for cancer patients. Targovax has a broad and diversified immune therapy portfolio and aim to become a leader in its area. The company is currently developing two complementary and highly targeted approaches in immuno-oncology.

ONCOS - 102 is a virus-based immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes targeting solid tumors. This treatment may reinstate the immune system's capacity to recognize and attack cancer cells.

TG01 and TG02 are part of a peptide-based immunotherapy platform targeting the difficult to treat RAS mutations found in more than 85% of pancreatic cancers, more than 50 % of colorectal cancer and 20-30% of all cancers. Targovax works towards demonstrating that TG vaccines will prolong time to cancer progression and increase survival.

The product candidates will be developed in combination with multiple treatments in several cancer indications, including checkpoint inhibitors. Targovax also has a number of other cancer immune therapy candidates in the early stage of development. For more information go to www.targovax.com.

For further information, please contact:

Gunnar Gårdemyr
CEO
Phone: +41 798 340 585
Email: ggardemyr@targovax.com

Øystein Soug
CFO
Phone: +47 906 56 525
Email: oystein.soug@targovax.com

HUG#2003231

Source: Targovax ASA